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Abstract. Functional diffusion mapping (fDM) is a cancer
imaging technique that quantifies voxelwise changes in
apparent diffusion coefficient (ADC). Previous studies have
shown value of fDMs in bevacizumab therapy for recurrent
glioblastoma multiforme (GBM). The aim of the present study
was to implement explicit criteria for diffusion MRI quality
control and independently evaluate fDM performance in a
multicenter clinical trial (RTOG 0625/ACRIN 6677). A total of
123 patients were enrolled in the current multicenter trial and
signed institutional review board-approved informed consent
at their respective institutions. MRI was acquired prior to and
8 weeks following therapy. A 5-point QC scoring system was
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used to evaluate DWI quality. fDM performance was evaluated
according to the correlation of these metrics with PFS and OS
at the first follow-up time-point. Results showed ADC variability of 7.3% in NAWM and 10.5% in CSF. A total of 68%
of patients had usable DWI data and 47% of patients had high
quality DWI data when also excluding patients that progressed
before the first follow-up. fDM performance was improved
by using only the highest quality DWI. High pre-treatment
contrast enhancing tumor volume was associated with shorter
PFS and OS. A high volume fraction of increasing ADC after
therapy was associated with shorter PFS, while a high volume
fraction of decreasing ADC was associated with shorter OS.
In summary, DWI in multicenter trials are currently of limited
value due to image quality. Improvements in consistency of
image quality in multicenter trials are necessary for further
advancement of DWI biomarkers.
Introduction
Approximately 20.6 people per 100,000 people in the United
States are diagnosed with a primary brain tumor each year (1).
GBM constitutes the most common and aggressive form of
malignant glioma, occurring in ~54% of gliomas (1) or 3.2
per 100,000 US citizens, and carrying a dismal prognosis of a
median survival of around 14 months (2) with <10% of patients
surviving beyond 5 years after diagnosis. Currently, the standard of care for newly diagnosed GBM patients consists of
maximum surgical resection, followed by radiotherapy plus
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concomitant and adjuvant temozolomide. At recurrence,
however, very few therapeutic options exist. Currently, no
treatment regimens have produced considerable therapeutic
benefit in recurrent GBM (3).
Bevacizumab, a monoclonal antibody to VEGF (4) is now
a common second-line treatment option for GBM patients that
have failed the standard of care, particularly due to an apparent
progression-free survival benefit shown in early clinical trials
(5-7) compared with historic controls (2). These early results
were based on a modified Macdonald criteria (8), which is
limited in the evaluation of anti-angiogenic treatments due
to the dramatic effect on vascular permeability resulting in
decreased contrast enhancement (9,10). Diffusion-sensitive
magnetic resonance imaging (MRI) biomarkers have shown
some early promise as predictive tools (11) in bevacizumab
therapy at recurrence. In particular, the functional diffusion
map (fDM) technique, which evaluates voxel-wise changes in
the apparent diffusion coefficient (ADC) over time, has shown
utility as an early response biomarker in bevacizumab therapy
in a single institution dataset consisting of uniform, highquality diffusion MRI data (11). This technique, however, has
not been evaluated in the context of a large multicenter trial
with mixed quality of diffusion MRI data.
The aim of the present study was to implement explicit
criteria for quality control and evaluate fDM performance
using DWI data collected as part of RTOG-0625, a multicenter,
randomized, phase II trial of bevacizumab with irinotecan or
temozolomide in recurrent GBM.
Materials and methods
The Radiation Therapy Oncology Group (RTOG), in collaboration with the American College of Radiology Imaging
Network (ACRIN), both funded by the National Cancer
Institute, conducted a prospective, randomized, phase II multicenter trial comparing bevacizumab with either irinotecan
or temozolomide treatment in recurrent GBM (RTOG 0625/
ACRIN 6677; ClinicalTrials.gov #NCT00433381; NCI-200900743). Twenty-four institutions both participated and had
diffusion MRI data available for analysis, each obtaining
institutional review board approval before subject accrual and
conducting the trial with Health Insurance Portability and
Accountability Act (HIPAA) compliance. Informed consent
was obtained for all subjects.
Study subjects. A total of 123 patients were enrolled in the
current trial (Table I). All patients had recurrent histologically proven GBM or gliosarcoma with progression on MRI
within 14 days after registration, ≥42 days after completion
of radiation/temozolomide therapy, ≥28 days after surgical
resection or cytotoxic therapy, as well as imaging or biopsy
confirmation of true progressive disease rather than radiation
necrosis after Gliadel placement or stereotactic radiosurgery.
Detailed inclusion and exclusion criteria are available at
http://www.acrin.org/Portals/0/Protocols/6677/RTOG%20
062-ACRIN%206677.pdf (Section 3.0). Bevacizumab was
administered to all patients (10 mg/kg intravenously, days 1
and 15 of a 28-day cycle). In the first arm, patients received
temozolomide (75 mg/m 2 per os, days 1-21 during the first
28-day cycle; 100 mg/m2 for cycle 2 and beyond in the absence

Table I. Summary of sites and number of patients enrolled.
Site
4205 - Barnes Jewish Hospital
4212 - Thomas Jefferson
4214 - MD Anderson
4217 - University of Iowa
4219 - Sloan Kettering
4220 - University of Rochester
4254 - Medical College of Wisconsin
4275 - Henry Ford
4283 – Akron General Medical Center
4372 - St. John's Health System
4399 - St. Luke's
4400 - Tel-Aviv Medical Center
4403 - Mt. Diablo
4404 - JFK
4405 - LDS
4406 - Arizona Oncology Serv @ SJHMC
4407 - Virginia Mason Medical Center
4409 - Carolina's Medical Center/Levine Cancer Ctr
4411 - N. Rockies Regional Cancer Center
4413 - Anne Arundel Medical Center
4414 - Alta Bates Comprehensive Cancer Center
4470 - Yale University
4492 - University of Chicago
4494 - UCLA
Total

No. of
patients
7
2
19
2
6
1
3
22
2
1
5
13
1
1
7
1
5
6
1
3
1
1
12
1

123

of myelotoxicity). In the second arm, patients received irinotecan (125 mg/m 2 intravenously, days 1 and 15 of a 28-day
cycle). Standard of care MRI occurred at baseline, after every
2 cycles of treatment (every 8 weeks), and after completion
or termination of treatment. Patients demonstrating benefit
(stable or responding tumor) were treated for 12 cycles with
optional extension to 24 cycles in the presence of continued
benefit and absence of severe toxicity.
Magnetic resonance imaging. Conventional MRI included precontrast T1-weighted, T2-weighted, T2-weighted FLAIR, and
diffusion-weighted MRI (DWI). After intravenous injection of
0.1 mmol/kg of standard gadolinium-based contrast, an axial
2D spin-echo and 3D volumetric T1-weighted (T1+C) images
were acquired. Patients participating in the optional advanced
component of the trial had dynamic contrast-enhanced MRI,
dynamic susceptibility contrast perfusion-weighted MRI,
and/or MR spectroscopy at baseline, week 2 and after every 2
cycles of treatment.
Diffusion MR acquisition parameters varied widely across
institutions despite specific ACRIN recommendations. Echo
time (TE) varied from 64 to 111.9 ms (~200%), and by as
much as 50% in the same patient during follow-up evaluations. Repetition time (TR) varied from 6 to 10 sec (~50%),
b-values ranged from 0 and 700 to 0 and 1,200 sec/mm2, and
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Table II. Quantitative quality control definitions for diffusion MRI and fDM analysis.
Parameter
Distortion/artifacts

Score = 1
(Unusable)
Severe,
affecting tumor

Score = 2
(Unusable)
Moderate,
affecting tumor

ADC values
Negative values Non-physiological
(NAWM)		
range (0-0.4 µm2/ms)
			
			
			
			

Score = 3
(Usable)
Moderate, not
affecting tumor

Score = 4
(Good)

Mild, not
No distortion or
affecting tumor artifacts

Lower or higher		
than normal, 		
but within
physiological range
(e.g. 0.4-0.6 µm2/ms;
0.8-1.0 µm2/ms)

ADC values (CSF) Negative values Non-physiological	Lower or higher		
		
range (0-1.5 µm2/ms; than normal,		
		
4.0+ µm2/ms)
but within
			
physiological range
Registration of ADC Severe
Moderately
Moderately
maps with
misalignment,
misaligned,
misaligned, but
Baseline
tumor not aligned tumor not aligned
tumor is aligned
ADC maps				

in some cases diffusion tensor imaging (6-12 directions) was
also acquired. In order to ensure relative consistency of ADC
calculations across sites, measures of ADC were obtained from
2 b-values (typically a single b=0 sec/mm2 image and an image
with higher diffusion weighting, or b=700-1200 sec/mm2. For
DTI data, average trace images were used for this higher diffusion weighted image).

Score = 5
(Great)

Within normal range
(0.6-0.8 µm2/ms)

Within normal range
for CSF

Slightly
Perfectly aligned
misaligned,
but tumor
is largely aligned

eters in Table II. Additionally, if DWI data were not available
for a particular patient, the QC score was zero.

Image registration. All images for each patient were registered
to their own pre-treatment, post-contrast, 3D T1-weighted
images with use of a mutual information algorithm and a
12-degree of freedom transformation using FSL (FMRIB;
http://www.fmrib.ox.ac.uk/fsl/). This was followed by visual
inspection to ensure adequate alignment. All images were
interpolated to the resolution of baseline post-contrast
T1-weighted images using trilinear interpolation. In cases with
significant mass effect, attempts were made to align tumor
regions exclusively. Regions of obvious misregistration (e.g.
near ventricles or edge of the brain) were excluded from final
fDM analysis.

Region of interest (ROI) determination. In the present study,
we chose to apply fDMs to regions of contrast-enhancing
tumor on pre-treatment, post-contrast T1-weighted images.
This approach has been shown to be the most predictive in
other treatment settings (11,12). Additionally, this time-point
likely contains the largest extent of contrast enhancing tumor
for use in fDM evaluation, since bevacizumab therapy results
in dramatic reduction of the volume of contrast enhancement in
the majority of patients. We used a semi-automated process of:
i) manually defining the relative region of tumor occurrence;
ii) thresholding the post-contrast images using an empirical
threshold combined with a region-growing algorithm; then iii)
manually editing the resulting masks to exclude any obvious
errors. For QC evaluations, a circular ROI (area, 1.5 cm 2 or
~1.4 cm diameter) was placed in the contra-lateral NAWM and
within the contra-lateral, anterior or posterior lateral ventricles
for a measure of normal CSF.

Quantitative quality control evaluation of diffusion MR data
and image registration. Quality control (QC) evaluation was
performed on both the diffusion MR data as well as the alignment between subsequent scans for use in fDM analysis. DWI
at each scan date were evaluated in terms of the following
factors: i) geometric distortion or artifacts on diffusion MR
datasets; ii) ADC values within normal appearing white matter
(NAWM) being within an acceptable range of ~0.4‑1.0 µm2/ms;
and iii) ADC values within cerebrospinal fluid (CSF) being
within an acceptable range of ~2.5-4.0 µm 2/ms. A 5-point
quantitative scaling scheme was used for each of these factors
as shown in Table II. The final QC score for each patient was
calculated as the minimum QC value from each of the param-

Functional diffusion map (fDM) calculation. After proper
registration was visually verified, voxel-wise subtraction was
performed between ADC maps acquired post-treatment and
baseline, pre-treatment ADC maps. Individual voxels were
stratified into three categories based on the change in ADC
relative to the baseline ADC map. Red voxels represented
areas where ADC increased beyond a ∆ ADC threshold of
0.4 µm 2/ms, or ADC(+), and blue voxels represented areas
where ADC decreased beyond a ∆ ADC threshold of 0.4 µm2/ms
or ADC(-). These ∆ ADC thresholds (±0.40 µm2/ms) represent
the 95% confidence interval for a mixture of normal appearing
gray and white matter estimated from 69 patients with various
tumor grades and follow-up time intervals ranging from

1886

ELLINGSON et al: Multicenter Evaluation of fDMs in Glioblastoma treated with Bevacizumab

1 week to 1 year post-baseline (13). The fraction of ADC(+) and
ADC(-) within the pre-treatment, post-contrast T1-weighted
images [%ADC(+) and %ADC(-)] was subsequently used for
fDM analysis.
Independent radiological facility definition of disease
progression. All local imaging was retrospectively transmitted to ACRIN for central review. Two primary readers
and one adjudicator, each with neuroradiology Certificates of
Added Qualification and 8, 6 and 3 years of post-fellowship
experience, respectively, were trained via teleconference
about 2D measurement techniques. Each primary reader was
assigned 2 similarly trained core laboratory technologist and
conducted independent image assessments. For each distinct
contrast-enhancing target lesion as defined by Macdonald and
RANO criteria (≥1 cm diameter, ≥1 cm from other enhancing
lesions), the largest diameter of contrast enhancement and its
maximum perpendicular diameter in the same plane were
measured. 2D tumor area was computed by summing over
all lesions the product of maximum perpendicular diameters.
Each reader determined time of progression on 2D postcontrast T1-weighted images when there was >25% increase
with respect to nadir in maximal cross-sectional enhancing
areas or the appearance of any new enhancing tumor (9,14).
Similarly, radiologic response was defined as ≥50% decrease
with respect to baseline, confirmed on the subsequent timepoint. Steroid dosage and clinical status were unavailable to
ACRIN readers for the present study. The adjudicator settled
discordant times to progression between primary readers by
selecting the times to progression that were most correct in
their opinion. The final measure of progression-free survival
(PFS) for the present study was defined as the time from the
first post-therapy scan used in fDM analysis until radiographic
progression.
Statistical analysis. A Kruskal-Wallis non-parametric test
was used to compare ADC measurements in normal tissue
across sites with 3 or more patients. Pooled variance twosample t-tests were used to compare pre-treatment enhancing
tumor volume, %ADC(+), or %ADC(-) between patients who
progressed/expired vs. were progression-free at 6 months and
those who expired at 12 months vs. those who were alive at
12 months from the first post-treatment MRI. Two-sample
Satterthwaite t-tests were used if group variances were significantly different. A Cox-regression model was used to evaluate
continuous measures of pre-treatment enhancing volume,
%ADC(+) or %ADC(-) adjusted for age and gender, where
the outcome was either PFS or overall survival (OS). Timedependent receiver operating characteristic (ROC) analysis
was performed for PFS or OS to determine the thresholds
for %ADC(+) and %ADC(-) that maximized Youden's index
(sensitivity+specificity-1). The threshold values were used
to divide %ADC(+) or %ADC(-) into two groups. Median
PFS and OS as well as their curves within each group were
estimated by the Kaplan-Meier method. Log-rank tests were
conducted to compare the PFS (or OS) curves between the two
groups of %ADC(+) [or %ADC(-)]. Data were examined separately for all usable DWI cases (QC ≥3) and cases with high
quality DWI data (QC=5) to illustrate the effects of image
quality on fDM analyses. P-values <0.05 were considered

significant and p-values <0.1 were considered trending toward
significance. All statistical data analyses were performed with
SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Normal tissue ADC and quality control assessment. The evaluation of pre-treatment ADC measurements within normal
tissues for different sites, MR manufacturers, and acquisition
techniques are shown in Fig. 1. In general, there was a wide
variation in diffusion measurements within the various tissue
types. The average coefficient of variance across all sites was
7.3% for NAWM and 10.5% for CSF. Kruskal-Wallis nonparametric comparisons of CSF and NAWM in sites with 3
or more patients suggested ADC varied significantly across
sites (NAWM, P<0.001; CSF, P<0.001). Closer examination
suggested that certain sites had systematically elevated or
suppressed estimates of ADC within normal tissues.
Of the 123 patients with diffusion data available, 84
patients (68%) had adequate image quality (QC score ≥3) and
58 patients (47%) had high quality data (QC score =5). Fig. 2
shows example diffusion MR images from patients for various
QC scores. The average QC score for all 123 patients was 3.37.
Of the 84 patients with adequate diffusion MR information,
ACRIN determined 3 cases ineligible for analysis, 3 cases
were withdrawn due to no evaluable contrast-enhancing tumor,
2 cases were excluded due to no baseline MR scan after registration to 6677, and 12 patients progressed prior to the first
imaging time-point, resulting in a total of 64 patients (52%)
of total enrolled patients with evaluable data for fDM analysis
(QC score ≥3) and a total of 46 patients (37%) of total enrolled
patients with high quality fDM data (QC score=5).
Study cohort and general fDM characteristics. Of the 64
patients with diffusion MR data available for fDM analysis
(QC ≥3), 34 patients were male and the mean age for all
patients was 57.3 years old ±11.2 sd. The average pre-treatment contrast enhancing volume was 18.5±16.9 cc sd, average
%ADC(+) was 17.8±14.4% sd, and average %ADC(-) was
20.6±17.9% sd.
Fig. 3 illustrates various examples of fDM response to
therapy, which in many cases appeared independent of changes
in anatomical images. For example, the patient in Fig. 3A
showed little change in contrast enhancement after therapy,
suggestive of stable disease or little response to therapy. fDM
results in this patient showed a relatively large proportion of
tumor with decreasing ADC (blue voxels), possibly suggestive
of growing tumor or increasing cell density. Conversely, the
patient shown in Fig. 3B demonstrated a similar change in
anatomical imaging response, but little change on fDMs. Some
patients showed a dramatic decrease in contrast enhancement
following therapy and little change in ADC, such as the patient
shown in Fig. 3C. Other patients showed a decrease in contrast
enhancement that was accompanied by an increase in ADC
(red voxels) similar to the patient shown in Fig. 3D.
Progression-free survival (PFS)
Patients with DWI QC ≥3. A total of 60 of 64 patients either
progressed or expired at the time of final evaluation, while
43 of 64 patients either progressed or expired at 6 months
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Figure 1. Mean ADC estimates for cerebrospinal fluid (CSF) and normal-appearing white matter (NAWM) across different sites, scanner manufacturers, and
field strengths. Kruskal-Wallis non-parametric comparisons of CSF and NAWM in sites with 3 or more patients suggested ADC varied significantly by site
(P<0.0001), with some sites showing systematically higher or lower ADC values in normal tissues.

Figure 2. Example images for QC scores resulting from varying degrees of geometric distortion in ADC maps. QC score = 5 (great) reflects high-quality
diffusion MRI data with no distortions. QC score = 4 (good) reflects mild geometric distortion that does not affect the tumor. QC score = 3 (usable) reflects
moderate geometric distortion not affecting the tumor. QC score = 2 (unusable) involves images with moderate distortion that is affecting measurement of the
tumor. QC score = 1 (unusable) involves severe distortion that is affecting measurement of the tumor.

from the first post-treatment time-point. Patients who were
progression-free at 6 months showed no significant differences
in pre-treatment volume of contrast enhancement and fDM

characteristics from those who progressed or expired before 6
months (P>0.05). Continuous measures of enhancing volume
were not significantly correlated with PFS (Cox regression:
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Figure 3. Examples of anatomical imaging and fDM response to bevacizumab and irinotecan or temozolomide. (A) This patient demonstrates a small change
in enhancing tumor volume, but a relatively large proportion of the tumor with decreasing ADC (blue voxels). (B) This patient shows a similar change in
enhancing tumor to the patient in (A), but shows very little change in ADC. (C) A patient with a dramatic change in contrast enhancement following therapy
that is not accompanied by a substantial change in ADC. (D) A patient with a decrease in contrast enhancement that involves a large proportion of the tumor
with increasing ADC (red voxels). Red voxels = ∆ ADC >+0.4 µm2/ms; blue voxels = ∆ ADC <-0.4 µm2/ms; green voxels = -0.4 µm2/ms ≤∆ ADC ≤+0.4 µm2/ms.

age, P= 0.153; gender, P= 0.214; pre-treatment enhancing
volume, P= 0.130); however, stratification of patients by median
pre-treatment volume of contrast enhancement (14.9 cc) did
show significant stratification of PFS (Fig. 4A; log-rank,

P= 0.003). Continuous measures of %ADC(+) and %ADC(-)
from fDM analysis were not significantly correlated with PFS
when adjusted for age and gender (Cox regression; P>0.05
for both %ADC(+) and %ADC(-)]. Youden's index suggested
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Figure 4. Pre-treatment contrast enhancing tumor volume and fDM response correlation of progression-free survival (PFS) for usable (QC ≥3) and high quality
(QC=5) DWI data. (A) Stratification of PFS based on pre-treatment contrast enhancing volume (T1+C) in patients with usable DWI data (log-rank, P=0.0026).
(B) Stratification of PFS based on the volume fraction of enhancing tumor with an increase in ADC [%ADC(+)] in patients with usable DWI data (log-rank,
P= 0.103). (C) Stratification of PFS based on the volume fraction of enhancing tumor with a decrease in ADC [%ADC(-)] in patients with usable DWI data
(log-rank, P= 0.166). (D) Stratification of PFS based on T1+C in patients with high quality DWI data (log-rank, P= 0.0106). (E) Stratification of PFS based on
%ADC(+) evaluated in patients with high quality DWI data (log-rank, P= 0.0421). (F) Stratification of PFS based on %ADC(-) evaluated in patients with high
quality DWI data (log-rank, P= 0.121).

Figure 5. Pre-treatment contrast enhancing tumor volume and fDM response correlation with overall survival (OS) for usable (QC ≥3) and high quality
(QC=5) DWI data. (A) Stratification of OS based on pre-treatment contrast enhancing volume (T1+C) in patients with usable DWI data (log-rank, P=0.125).
(B) Stratification of OS based on volume fraction of enhancing tumor with an increase in ADC [%ADC(+)] in patients with usable DWI data (log-rank,
P= 0.158). (C) Stratification of OS based on volume fraction of enhancing tumor with a decrease in ADC [%ADC(-)] in patients with usable DWI data (log-rank,
P= 0.219). (D) Stratification of OS based on T1+C evaluated for patients with high quality DWI data (log-rank, P= 0.099). (E) Stratification of OS based on
%ADC(+) in patients with high quality DWI data (log-rank, P= 0.668). (F) Stratification of OS based on %ADC(-) evaluated in patients with high quality DWI
data (log-rank, P= 0.0346).
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an optimal cutpoint of %ADC(+) of 20.5% and %ADC(-) of
2.7% for PFS. Using these thresholds, patients with a large
volume fraction of pre-treatment enhancing tumor with
increasing ADC, or %ADC(+) >20.5 cc, had slightly worse
PFS (median PFS = 167 vs. 98 days); however, this was not
statistically significant (Fig. 4B; log-rank, P= 0.103). Results
also suggest patients with a large volume fraction of pre-treatment enhancing tumor with decreasing ADC at follow-up, or
%ADC(-) >2.7, had a slightly shorter PFS (median PFS = 107
vs. 240 days), but this was also not statistically significant
(Fig. 4C; log-rank, P= 0.116).
Patients with DWI QC=5. For patients with high quality
DWI data, a significant difference in pre-treatment contrast
enhancing volume was observed between patients who
were progression-free at 6 months and those who expired
or progressed before 6 months (11.6 vs. 19.9 cc, P= 0.027),
but no significant differences were found in fDM characteristics between these patients (P>0.05). Continuous
measures of pre-treatment contrast-enhancing tumor volume
were significantly correlated with PFS (Cox regression:
age, P= 0.196; gender, P= 0.810; pre-treatment enhancing
volume, P= 0.012). Consistent with these trends, stratification of patients by median pre-treatment volume of contrast
enhancement (14.3 cc) demonstrated significant stratification
of PFS (Fig. 4D; log-rank, P= 0.011). Continuous measures of
%ADC(+) and %ADC(-) from fDM analysis were not significant predictors for PFS when accounting for age and gender
[Cox regression: P>0.05 for both %ADC(+) and %ADC(-)].
Youden's index suggested a threshold of %ADC(+) of 27.4%
and %ADC(-) of 2.7% for PFS in patients with high quality
DWI. Results suggest patients with a large volume fraction
of pre-treatment enhancing tumor with increasing ADC or
%ADC(+) >27.4%, had significantly shorter PFS (Fig. 4E;
median PFS =77 vs. 120 days; log-rank, P=0.042). Results
also suggest patients with a large volume fraction of pretreatment enhancing tumor with decreasing ADC at follow-up
or %ADC(-) >2.7%, had a slightly shorter PFS (median PFS
= 107 vs. 240 days), but this was not statistically significant
(Fig. 4F; log-rank, P= 0.121).
Overall survival (OS). A total of 56 of 64 patients with
evaluable DWI expired by the end of the study, while 45 of
64 patients expired by 12 months from the first post-treatment
time-point. No difference in mean pre-treatment contrast
enhancing volume or fDM characteristics were observed
between patients alive at 12 months compared with those who
expired at 12 months (P>0.05 for all metrics).
Patients with DWI QC ≥3. Neither continuous measures of
enhancing volume or fDM characteristics were significant
predictors for OS [Cox, P>0.05 for volume, %ADC(+) and
%ADC(-)]. When patients were stratified by median pretreatment contrast-enhancing tumor volume (14.9 cc), no
significant difference in OS was observed (Fig. 5A; log-rank,
P= 0.125). Th optimal cutpoints for %ADC(+) and %ADC(-)
were 17.3 and 26.2% when the outcome was OS; however,
neither %ADC(+) (Fig. 5B; log-rank, P= 0.158) nor %ADC(-)
(Fig. 5C; log-rank, P= 0.219) significantly separated these
groups in terms of OS.

Patients with DWI QC=5. For patients with high quality DWI
data available, continuous measures of pre-treatment contrastenhancing tumor was significantly correlated with OS (Cox,
P= 0.006 for volume, P= 0.080 for age and 0.575 for gender).
When patients were stratified by median pre-treatment
enhancing volume (14.3 cc), a trend toward a difference in
OS was observed (Fig. 5D; log-rank, P= 0.099). Continuous
measures of %ADC(+) and %ADC(-) were not significantly
associated with OS (Cox, P>0.05 for fDM metrics). The
optimal cutpoints for %ADC(+) and %ADC(-) in patients with
high quality DWI data were 15.2 and 3.97%, respectively. The
Kaplan-Meier curves between the two groups of %ADC(+)
were not significantly different (Fig. 5E; log-rank, P= 0.668).
On the other hand, patients with a large volume fraction of pretreatment enhancing tumor with decreasing ADC at follow-up,
or %ADC(-) >3.97%, had a significantly shorter OS (Fig. 5F;
median OS = 210 vs. 413 days; log-rank, P=0.035).
Discussion
To the best of our knowledge, this is one of the first studies
to define and implement specific diffusion MRI quality
control criteria in the setting of a multicenter clinical trial
in brain cancer. Results from the present study showed
~7.3-10.5% coefficient of variance in measurement of ADC
across various sites. These results appear consistent with the
measurements obtained by Chenevert et al (15), who estimated the variability of ADC in an ideal setting of an ice
water phantom at ~5% when evaluated across vendors and
platforms. It is important to note, however, that measures
of ADC within a water phantom is monoexponential, thus,
measurements of ADC may be quite resilient to the number
of b-values and maximum b-value chosen, which may not be
the case with normal neural tissues. More importantly, only
84 of the original 123 (68%) patients had usable DWI data
free of distortion around the areas of tumor and only 58 of
the original 123 (47%) patients had high quality DWI data
with no distortions or ADC abnormalities. [In the end, only
64 patients (52%) had usable DWI data and 46 patients (37%)
had high quality DWI data after patients were excluded based
on other factors]. This degree of unusable data is particularly
discouraging if diffusion MRI is to be considered a secondary
response biomarker or a potential imaging endpoint in future
prospective multicenter clinical trials.
The present study clearly demonstrates the importance of
performing semi-quantitative QC in the context of advanced
imaging in multicenter clinical trials. Functional diffusion
mapping using high quality diffusion MRI acquired before
and after administration of bevacizumab is a valuable imaging
biomarker for predicting survival in recurrent glioblastoma
patients treated with bevacizumab. Almost all fDM metrics
showed improved stratification of short- and long-term PFS
and OS when examining the highest quality DWI data (QC=5)
compared with usable DWI data (QC ≥3). In particular,
examination of high quality DWI data showed significant
stratification of short- and long-term PFS when examining
the volume fraction of pre-treatment enhancing tumor with
increasing ADC [%ADC(+)], while the volume fraction of
enhancing tumor with decreasing ADC [%ADC(-)] showed
significant stratification of short- and long-term OS. When
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examining only the usable DWI data (QC ≥3), these trends
were not statistically significant.
Although only a subset of data was evaluable in the present
multicenter study, fDM results appeared to show some trends
that were consistent and other trends that were inconsistent
with previous studies. For example, previous fDM studies
involving radiochemotherapy (12,16,17) in newly diagnosed
malignant gliomas and bevacizumab (11) in recurrent GBM
showed that patients with a low volume fraction of tumor with
decreasing ADC [%ADC(-)] were more likely to have a longer
PFS and OS. In the present study, we observed the same trend,
however, results only showed statistical significance when
examining %ADC(-) in terms of OS the subset of patients with
high quality DWI data. Contrary to previous fDM reports,
patients exhibiting a large volume fraction of enhancing
tumor demonstrating an increase in ADC at first follow-up
[%ADC(+)] appeared more likely to progress earlier than
patients with a small volume fraction. Since all these patients
were treated with bevacizumab, which tends to rapidly reduce
the amount of vasogenic edema, it is conceivable that tumors
demonstrating an increase in ADC following bevacizumab
may represent those tumors to which vascular permeability
has increased, indicating ineffective anti-angiogenic therapy.
It is important to point out that pre-treatment contrast
enhancing tumor volume was one of the strongest correlates of
survival in recurrent GBM patients treated with bevacizumab
and chemotherapy. Results from the present study suggest that
continuous measures of pre-treatment enhancing tumor were
significantly correlated with PFS and OS when accounting for
clinical covariates, particularly when examining patients with
the highest quality MR data. This observation is consistent
with a recent study (18) examining contrast enhancing tumor
before and after bevacizumab treatment in a similarly structured phase II multicenter study in recurrent GBM patients
treated with bevacizumab monotherapy or bevcizumab and
irinotecan. As measures of contrast enhancing tumor remain
the gold standard for response assessment and estimating
tumor burden in malignant gliomas, it is important to compare
emerging imaging biomarkers with this standard to determine
if they truly add clinical benefit.
A number of limitations and possible explanations for the
relatively poor fDM performance should be addressed. First,
the present study involved calculation of ADC given only 2
b-values, while the National Cancer Institute recommends that
at least 3 b-values be acquired (0, >100 and >500 sec/mm 2)
for estimation of perfusion-insensitive ADC (19). Additionally,
many sites did not comply with the recommended diffusion
MRI protocols, nor was there a mechanism in place for
real-time feedback of image quality as diffusion MRI was
considered a secondary measurement to standard anatomic
imaging techniques. Another potential limitation was the
potential influence of geometric distortions on ADC measurements. Woodworth et al (20) recently showed that post hoc
non-linear distortion correction of diffusion MR images to
high-resolution T2-weighted images can improve diffusion
measurements in brain tumors, demonstrating that subtle
distortions can cause significant differences in ADC measurements. A similar approach could have been used in the present
study to improve ADC measurements, even in patients with
usable data (QC ≥3). Similarly, the use of a rigid-body image
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registration algorithm to align serial ADC maps to baseline
ADC maps poses another potential limitation. Significant
changes in mass effect from tumor growth or shrinkage, or
intracranial pressure changes induced by changes in the
extent of vasogenic edema may cause inaccuracies in the
alignment between the diffusion MR datasets. A recent study
by Ellingson et al (21) showed improved fDM performance
in the context of bevacizumab therapy by using non-linear
registration of ADC maps over time. It is conceivable that a
similar approach may also have improved fDM performance
in the context of the current study, which also involved similar
therapies and registration challenges.
In conclusion, the present study suggests diffusion MRI
data collected as part of a multicenter trial for brain tumors
may be of limited value, due particularly to the wide variety in
image quality across sites, vendors and acquisition protocols.
In data deemed usable, fDM results showed similar trends but
lower correlations compared with previous single-institution
trials involving relatively high-quality diffusion data with
homogeneous acquisition protocols. Stratification of survival
using fDM metrics were substantially improved by examining
a subset of patients with high quality DWI data, suggesting
image quality may have a significant impact on fDM performance. Future studies aimed at improving the consistency of
image quality in multicenter trials are necessary for further
advancement of diffusion MR biomarkers.
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